TScan Therapeutics, Inc.
TCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $188,109 | $178,956 | $367,200 |
| - Cash | $169,506 | $169,394 | $154,108 | $178,689 |
| + Debt | $88,718 | $64,404 | $97,037 | $97,381 |
| Enterprise Value | – | $83,119 | $121,885 | $285,892 |
| Revenue | $2,511 | $3,076 | $2,171 | $665 |
| % Growth | -18.4% | 41.7% | 226.5% | – |
| Gross Profit | $1,744 | $3,076 | $2,171 | $665 |
| % Margin | 69.5% | 100% | 100% | 100% |
| EBITDA | -$34,244 | -$35,565 | -$32,770 | -$34,314 |
| % Margin | -1,363.8% | -1,156.2% | -1,509.4% | -5,160% |
| Net Income | -$35,710 | -$36,952 | -$34,127 | -$35,809 |
| % Margin | -1,422.1% | -1,201.3% | -1,571.9% | -5,384.8% |
| EPS Diluted | -0.28 | -0.28 | -0.26 | -0.3 |
| % Growth | 0% | -7.7% | 13.3% | – |
| Operating Cash Flow | -$32,464 | -$33,267 | -$37,586 | -$27,412 |
| Capital Expenditures | -$1,425 | -$1,279 | -$1,532 | -$888 |
| Free Cash Flow | -$33,889 | -$34,546 | -$39,118 | -$28,300 |